POLX.F logo

Polydex Pharmaceuticals Limited Stock Price

OTCPK:POLX.F Community·US$6.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 0 Fair Values set on narratives written by author

POLX.F Share Price Performance

US$0
0.00 (0.00%)
US$0
0.00 (0.00%)
Price US$0

POLX.F Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Adequate balance sheet and slightly overvalued.

3 Risks
0 Rewards

Polydex Pharmaceuticals Limited Key Details

US$4.7m

Revenue

US$4.6m

Cost of Revenue

US$142.9k

Gross Profit

US$985.1k

Other Expenses

-US$842.3k

Earnings

Last Reported Earnings
Apr 30, 2023
Next Reporting Earnings
n/a
-0.25
3.01%
-17.76%
2.8%
View Full Analysis

About POLX.F

Founded
1979
Employees
20
CEO
George Usher
WebsiteView website
www.polydex.com

Polydex Pharmaceuticals Limited, through its subsidiaries, develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market worldwide. The company also manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry. It primarily offers dextran and derivative products, including iron dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. Further, it supplies ferric hydroxide and hydrogenated dextran solutions. The company sells its products through independent distributors and wholesalers, as well as directly to companies. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was incorporated in 1979 and is based in Toronto, Canada.

Recent POLX.F News & Updates

Recent updates

No updates